These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32562892)

  • 1. Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom.
    Rice S; Albani V; Minos D; Fattakhova G; Mells GF; Carbone M; Flack S; Varvaropoulou N; Badrock J; Spicer A; Sandford RN; Shirley MDF; Coughlan D; Hirschfield G; Taylor-Robinson SD; ; Vale L; Jones DEJ
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):768-776.e10. PubMed ID: 32562892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis.
    Pasha T; Heathcote J; Gabriel S; Cauch-Dudek K; Jorgensen R; Therneau T; Dickson ER; Lindor KD
    Hepatology; 1999 Jan; 29(1):21-6. PubMed ID: 9862844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of PBC-specific health-related quality of life questionnaires in patients with primary sclerosing cholangitis.
    Raszeja-Wyszomirska J; Wunsch E; Krawczyk M; Rigopoulou EI; Bogdanos D; Milkiewicz P
    Liver Int; 2015 Jun; 35(6):1764-71. PubMed ID: 25388280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists.
    Webb GJ; Rana A; Hodson J; Akhtar MZ; Ferguson JW; Neuberger JM; Vierling JM; Hirschfield GM
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):278-287.e7. PubMed ID: 28993258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.
    Samur S; Klebanoff M; Banken R; Pratt DS; Chapman R; Ollendorf DA; Loos AM; Corey K; Hur C; Chhatwal J
    Hepatology; 2017 Mar; 65(3):920-928. PubMed ID: 27906472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort.
    Pells G; Mells GF; Carbone M; Newton JL; Bathgate AJ; Burroughs AK; Heneghan MA; Neuberger JM; Day DB; Ducker SJ; ; Sandford RN; Alexander GJ; Jones DE
    J Hepatol; 2013 Jul; 59(1):67-73. PubMed ID: 23466308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of ERN RARE-LIVER online survey.
    Wunsch E; Krause L; Gevers TJ; Schramm C; Janik MK; Krawczyk M; Willemse J; Uhlenbusch N; Löwe B; Lohse AW; Milkiewicz P
    Liver Int; 2023 Feb; 43(2):381-392. PubMed ID: 36177700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
    Bowlus CL; Kenney JT; Rice G; Navarro R
    J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery.
    Abbas N; Smith R; Flack S; Bains V; Aspinall RJ; Jones RL; Burke L; Thorburn D; Heneghan M; Yeoman A; Leithead J; Braniff C; Robertson A; Mitchell C; Thain C; Mitchell-Thain R; Jones D; Trivedi PJ; Mells GF; Alrubaiy L;
    JHEP Rep; 2024 Jan; 6(1):100931. PubMed ID: 38089546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
    Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid.
    Boberg KM; Wisløff T; Kjøllesdal KS; Støvring H; Kristiansen IS
    Aliment Pharmacol Ther; 2013 Oct; 38(7):794-803. PubMed ID: 23915021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.
    Angelis A; Kanavos P; López-Bastida J; Linertová R; Nicod E; Serrano-Aguilar P;
    BMC Health Serv Res; 2015 Sep; 15():428. PubMed ID: 26416027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis.
    Jacoby A; Rannard A; Buck D; Bhala N; Newton JL; James OF; Jones DE
    Gut; 2005 Nov; 54(11):1622-9. PubMed ID: 15961522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of liver transplantation on health-related quality of life in patients with primary biliary cholangitis.
    Krawczyk M; Koźma M; Szymańska A; Leszko K; Przedniczek M; Mucha K; Foroncewicz B; Pączek L; Moszczuk B; Milkiewicz P; Raszeja-Wyszomirska J
    Clin Transplant; 2018 Dec; 32(12):e13434. PubMed ID: 30362634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
    Hirschfield GM; Dyson JK; Alexander GJM; Chapman MH; Collier J; Hübscher S; Patanwala I; Pereira SP; Thain C; Thorburn D; Tiniakos D; Walmsley M; Webster G; Jones DEJ
    Gut; 2018 Sep; 67(9):1568-1594. PubMed ID: 29593060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized crossover trial to assess therapeutic efficacy and cost reduction of acid ursodeoxycholic manufactured by the university hospital for the treatment of primary biliary cholangitis.
    Nakano LA; Cançado ELR; Chaves CE; Madeira MCV; Katayose JT; Nabeshima MA; Fossaluza V; Uhrigshardt GG; Liting Z; Pinto VB; Carrilho FJ; Ono SK
    BMC Gastroenterol; 2020 Aug; 20(1):253. PubMed ID: 32758152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Socioeconomic costs and health-related quality of life in juvenile idiopathic arthritis: a cost-of-illness study in the United Kingdom.
    Angelis A; Kanavos P; López-Bastida J; Linertová R; Serrano-Aguilar P;
    BMC Musculoskelet Disord; 2016 Aug; 17():321. PubMed ID: 27484740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
    J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study.
    Carbone M; Bufton S; Monaco A; Griffiths L; Jones DE; Neuberger JM
    J Hepatol; 2013 Sep; 59(3):490-4. PubMed ID: 23628322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.